2025
Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden
Malinga J, Braunack-Mayer L, Masserey T, Cavelan A, Chandramohan D, Dicko A, Ouédraogo J, Kelly S, Le Rutte E, Nekkab N, Penny M. Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden. PLOS Global Public Health 2025, 5: e0004549. PMID: 40758687, PMCID: PMC12321141, DOI: 10.1371/journal.pgph.0004549.Peer-Reviewed Original ResearchPre-erythrocytic vaccineMalaria vaccineChildhood malariaDuration of protectionIndividual-based model of malaria transmissionPre-erythrocytic malaria vaccineModel of malaria transmissionMalaria vaccine developmentRTS,SSevere childhood malariaRTS,S/AS01Public health impactIncidence reductionRoutine immunization programSeasonal vaccineMalaria transmissionClinical endpointsPotential public health impactVaccine efficacyPrimary vaccinationYear boosterMalariaVaccine developmentVaccine propertiesTrial data
2018
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules
Moïsi J, Yaro S, Kroman S, Gouem C, Bayane D, Ganama S, Meda B, Nacro B, Njanpop-Lafourcade B, Ouangraoua S, Ouedraogo I, Sakande S, Sawadogo F, Zida S, Ouedraogo J, Gessner B. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 422-432. PMID: 30299491, DOI: 10.1093/jpids/piy075.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntibodies, BacterialBurkina FasoChild, PreschoolFemaleHumansImmunization ScheduleImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInfantMaleOpsonin ProteinsPhagocytosisPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal conjugate vaccineMonths of ageConjugate vaccineStudy armsImmune responseDoses of PCVAge groupsDoses 2 monthsSerum immunoglobulin G concentrationBurden of morbidityStreptococcus pneumoniae infectionStrong primary immune responsesRoutine immunization programPrimary immune responseRobust memory responsesMajority of serotypesYears of ageWeeks of ageImmunoglobulin G concentrationBooster doseReactogenicity dataReactogenicity profileSatisfactory immunogenicityOpsonophagocytic activityPneumoniae infection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply